Newsroom | 4330 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, is presenting preclinical data demonstrating first-in-industry targeted degradation of ERG at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which begins today in Chicago, Illinois. ERG has been a long-recognized high-value target in prostate cancer, where ERG fusio...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment an...

NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three posters at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois (25-30 April). The posters cover the Company’s new payload class, the ProAlk series, its CA242-directed ADC, IKS04, being developed for the treatment of gastrointestinal (GI) cancers, and its proprietary P...

SALT LAKE CITY--(BUSINESS WIRE)--Q2FY25 earnings date & time announcement...

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a global leader in breast health technology, will feature its latest advancements in diagnostic accuracy and patient-centered breast care during the 2025 Society of Breast Imaging Symposium in Colorado Springs, Co., April 24-27, 2025. This year’s showcase will feature new innovations designed to improve breast cancer detection, streamline workflows, and enhance overall patient care. Mammography innovations streamline exam w...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, éligible PEA/PME, « Median » ou « La Société ») fabricant d’eyonis™, une suite de logiciels dispositifs médicaux basés sur l’intelligence artificielle (IA) pour le diagnostic précoce des cancers, et un leader mondial de la fourniture d’analyses d’images par IA et de services centraux d’imagerie pour les essais cliniques en oncologie de l’industrie biopharmaceutique, communique aujourd’hui ses i...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, releases today its Q1 2025 key financial indicators (unaudited) and provides an update on...

DUBLIN--(BUSINESS WIRE)--The "Magnetic Resonance Imaging (MRI) Equipment - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. MRI systems remain a cornerstone in today’s medical imaging landscape, aiding in the diagnosis and management of various chronic conditions. These non-invasive devices are favoured for their precision and safety, significantly overshadowing ionizing radiation methods, despite certain limitations for patients with metallic implants and s...

MARTIGNY, Svizzera e DIGIONE, Francia--(BUSINESS WIRE)--Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), un'azienda biofarmaceutica globale con sede in Svizzera che opera nell'ambito della cura del cancro e delle malattie infettive, e Oncodesign Services (www.oncodesign-services.com), una CRO leader specializzata nella scoperta di farmaci e nei servizi preclinici, hanno annunciato la sottoscrizione di un accordo di licenza per l'uso della tecnologia AbYlink™ per i...

MARTIGNY, Zwitserland & DIJON, Frankrijk--(BUSINESS WIRE)--Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), een internationaal biofarmaceuticabedrijf gevestigd in Zwitserland dat zich tot doel stelt om kanker en besmettelijke ziekten te behandelen, en Oncodesign Services (www.oncodesign-services.com), een toonaangevende CRO gespecialiseerd in het ontdekken van geneesmiddelen en preklinische services, kondigen de uitvoering aan van een licentieakkoord voor het gebru...